Sage / DREAM Breast Cancer Prognosis Challenge The goal of the breast cancer prognosis challenge is to assess the accuracy of computational models designed.

Slides:



Advertisements
Similar presentations
Understanding Genome-Wide Profiling of Cancer
Advertisements

Ulrik Lassen MD, PH.D Phase 1 Unit
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
Recursive Partitioning Method on Survival Outcomes for Personalized Medicine 2nd International Conference on Predictive, Preventive and Personalized Medicine.
Computational Diagnostics We are a new research group in the department of Computational Molecular Biology at the Max Planck Institute for Molecular Genetics.
Personalized Medicine
3 rd Summer School in Computational Biology September 10, 2014 Frank Emmert-Streib & Salissou Moutari Computational Biology and Machine Learning Laboratory.
Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.
OncoTracker James Berenson, MD President and CEO November 2014.
Emergent Biology Through Integration and Mining Of Microarray Datasets Lance D. Miller GIS Microarray & Expression Genomics.
Clinical Trials The Way We Make Progress Against Disease.
Opportunity and Pitfalls in Cancer Prediction, Prognosis and Prevention Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
MammaPrint, the story of the 70-gene profile
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Simple. Scientifically Informed Medical Practice and Learning Suzana Alves da Silva, MD, MSc, PhD, FNYAM 2014 TEACH Workshop THE SECTION ON Evidence Based.
Crowdsourcing pharmacogenomic data analysis: PGRN-Sage RA Responder Challenge PGRN Spring Meeting April 30, 2013 HARVARD MEDICAL SCHOOL.
The virochip (UCSF) is a spotted microarray. Hybridization of a clinical RNA (cDNA) sample can identify specific viral expression.
Sage Bionetworks Mission Sage Bionetworks is a non-profit organization with a vision to create a “commons” where integrative bionetworks are evolved by.
Exagen Diagnostics, Inc., all rights reserved Biomarker Discovery in Genomic Data with Partial Clinical Annotation Cole Harris, Noushin Ghaffari.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.
BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
COMPUTATIONAL ANALYSIS OF MULTILEVEL OMICS DATA FOR THE ELUCIDATION OF MOLECULAR MECHANISMS OF CANCER Presented by Azeez Ayomide Fatai Supervisor: Junaid.
Sage / DREAM Breast Cancer Prognosis Challenge The goal of the breast cancer prognosis challenge is to assess the accuracy of computational models designed.
World Cancer Assay Markets Human Genome Project Drives Industry Developments “The Human Genome Project has generated a tremendous amount of information.
Prostate Cancer Management: A Guide for Patients and Caregivers
A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Global Cancer Biomarkers Market
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Illustration of how the diagnostic yield changes as the size of the gene panel (number of genes) increases. The general characteristics of panels of various.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Biomarkers.
Advances in Personalized Medicine in Oncology: A Refresher for the Practicing Radiation Therapist Sophia Lamey 
NCT: Gaining Medical Insights and Enhancing Care for Cancer Patients with SAP HANA® Organization National Center for Tumor Diseases (NCT) Heidelberg, part.
GENETIC BIOMARKERS.
An Artificial Intelligence Approach to Precision Oncology
Data-Drive Analytics for Precision Medicine
MR images analysis of glioma
P. Therasse, S. Carbonnelle, J. Bogaerts 
Dept of Biomedical Informatics University of Pittsburgh
The Genomics of Cancer and Molecular Testing:
Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors  Manny D. Bacolod, Francis Barany 
Transcriptional Signature of Histone Deacetylases in Breast cancer
Genomic alterations in breast cancer cell line MDA-MB-231.
Implementing Genome-Driven Oncology
Clinical Genomics in Inflammatory Bowel Disease
Volume 155, Issue 6, Pages (December 2018)
Molecular prognostication of liver cancer: End of the beginning
Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors  Manny D. Bacolod, Francis Barany 
12th – 13th November GRANADA
Knowledge-Guided Sample Clustering
Medical Informatics and Explainable AI
Next Generation Sequencing Market. Report Description and Highlights According to Renub Research market research report “Next Generation Sequencing (NGS)
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
How Is Precision Medicine Transforming The Health Care Industry?
Presentation transcript:

Sage / DREAM Breast Cancer Prognosis Challenge The goal of the breast cancer prognosis challenge is to assess the accuracy of computational models designed to predict breast cancer survival based on clinical information about the patient's tumor as well as genome-wide molecular profiling data including gene expression and copy number profiles. More… (next page)

Sage / DREAM Breast Cancer Prognosis Challenge Clinical Problem Molecular diagnostics for cancer therapeutic decision making are among the most promising applications of genomic technology. Several diagnostic tests have gained regulatory approval in recent years. Molecular profiles have proved particularly powerful in adding molecular information to standard clinical practice in breast cancer, using gene-expression-based diagnostic tests such as Mammaprint and Oncotype Dx. The exciting phase of “Precision Medicine”, as defined by the Institute of Medicine Report last year, proposes a world where medical decisions will be guided by molecular markers that ensure that therapies are tailored to the patients that receive them. The most exciting topics at the FDA and in the scientific community revolve around – “how can we leverage genomic information to determine who should and should not get which therapies?” Data Formats Survival data Survival data is loaded into R as a Surv object as defined in the R survivalpackage. This object is simply a 2 column matrix with sample names on the rows and columns: – time – time from diagnosis to last follow up. – status – weather the patient was alive at last follow up time. Feature data Gene expression data. – Performed on the Illumina HT 12v3 platform and normalized using XXXX. – Loaded as Bioconductor ExpressionSet object with columns corresponding to samples and rows corresponding to Illumina probes. Copy number data. – Performed on the Affymetrix SNP 6.0 platform and normalized using XXX. – Loaded as Bioconductor ExpressionSet object with columns corresponding to samples and rows corresponding to segmented copy number regions (??). Clinical covariates. For a detailed explanation of the clinical data and how it is currently used in breast cancer prognosis and treatment, see Breast Cancer Challenge clinical background.Breast Cancer Challenge clinical background R-Studio Tutorial Discussion Forum Google Technical Guide Join the Challenge Contest Computing Facilities Powered by Google (open dialog shown on next page)

Sage/DREAM Application to Participate First name: Joe Last name: Hellerstein jl at google.com Organization: IBM Phone: (123) You will be notified by when your application is approved. Submit Cancel